Search

everythinglearnresearchcommunity

for

Search:↓

Androgen receptor inactivation delays skin cancer onset and reduces incidence in mice, with gender differences in susceptibility.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

Researchers made new compounds that could potentially be developed into anticancer drugs.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Newer retinoid drugs are effective for skin conditions but have significant side effects.

Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Androgens may influence bladder cancer progression by affecting cellular behavior.

GLP-1 receptor agonists may cause hair loss, but regrowth is rare.

These medications for BPH have known risks and may have new side effects.

Letrozole may help prevent seizures by reducing certain hormone levels.

Higher levels of miR-1199-5p may reduce the effectiveness of certain prostate treatments.

Certain compounds reduced hamster flank organ size by inhibiting 5α-reductase, like finasteride, without affecting androgen receptors.

Baricitinib is an effective treatment for severe alopecia areata.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.

An oil-in-water emulsion with CBD and ginger root extract significantly improved symptoms of dry and eczema-prone skin.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.

The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

A new mutation in the CYP11B1 gene was found in a woman with mild hyperandrogenemia, a rare cause of non-classic congenital adrenal hyperplasia.

Androgen receptors are active in many tissues of both male and female mice, not just reproductive organs.

β-Sitosterol may help prevent heart disease, cancer, and diabetes, but more human studies are needed.

Dopamine affects coat color changes in agouti mice.

Germacrene analogs, especially 8-Hydroxy germacrene B, are more effective than germacrone at blocking a hormone-related enzyme and could help treat hair loss.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Baricitinib is a promising treatment for alopecia areata.